Due to the special nature of medicines, returns and exchanges are not supported.
Final delivery from the nearest overseas warehous NEW

Dalpiciclib Isethionate Tablets

This product, combined with fulvestrant, is indicated for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer who have progressed after previous endocrine therapy. [1]
This product, combined with an aromatase inhibitor as initial treatment, is indicated for patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. [9]

Brand: pill Categories:

Share: